LBSP Favicon

Leiden University launches short courses for professionals in data, AI, and mathematics

The Faculty of Science at Leiden University is offering a new opportunity for professionals to deepen their knowledge of data-driven decision-making, complex systems, and algorithmic thinking. As part of a […]

The Faculty of Science at Leiden University is offering a new opportunity for professionals to deepen their knowledge of data-driven decision-making, complex systems, and algorithmic thinking.

As part of a national pilot on microcredentials, three English-taught courses will be available this September through the Mathematical Institute (MI):

  • Complex Networks: Learn how to analyze and influence systems like traffic flows, social media, and energy networks.

  • Interactive Machine Learning: Explore how algorithms can adapt and support decision-making under uncertainty.

  • Algorithms in Algebra: Gain insight into the mathematics behind algorithms with applications in cryptography and computational science.

Each course provides practical tools and academic rigor, and participants will receive a microcredential, a digital certificate that can be added to their CV and LinkedIn profile.

Courses are held in person at the Gorlaeus building in Leiden and run during the first semester of the academic year. Registration is open until 15 August 2025.

Learn more: https://www.universiteitleiden.nl/wiskunde-en-natuurwetenschappen/onderwijs/onderwijs-voor-professionals

These courses are especially relevant for professionals in biotech, data science, or engineering fields who want to strengthen their analytical and modeling skills.

For questions or collaboration inquiries, contact Leontine Heisen, Senior Communications Advisor at the Faculty of Science.

Related posts

VarmX Secures IND Approval for Phase 3 Trial of VMX-C001 in Emergency Surgery

VarmX Secures IND Approval for Phase 3 Trial of VMX-C001 in Emergency Surgery

VarmX has received IND approval for its Phase 3 trial of VMX‑C001, a recombinant factor X variant designed to neutralize FXa‑inhibiting anticoagulants during emergency surgery. Backed by robust Phase 1 data and boosted by a €15 million EIC investment, this step positions VMX‑C001 to meet a gap in urgent haemostasis care.